The ethanol production was determined using Anton Paar Alcolyzer and the end glucose concentration using a commercial GOD-PAP assay (Dialab).
Serum cholesterol and triglycerides were determined by Ecoline CHOD-PAP and Ecoline 25 GPO-PAP assay kits (1.14856.0001, Merck KGaA, Darmstadt, Germany), respectively.
A cocktail of MAP assays for the common 15/18 bp deletions, together with a Bi-PAP-A assay for the common L858R mutation, could detect about 70 80% of EGFR mutations constituting about 10% of total lung cancers [10], [36].
However, the high baseline frequency of the deaminated cytosine and 8-oxo-guanidine in genomic DNA limits the analytical selectivity of C>T or G>T by Bi-PAP-A assays to >104 and >105, respectively.
On that basis, we assayed PAP I in serum from patients with chronic hepatitis, liver cirrhosis or hepatocarcinoma.
The triglyceride concentration was determined by GPO-PAP enzymatic, photometric assay (Konelab TRIGLYCERIDES kit, Thermo Electron Co, Finland) and the total serum cholesterol concentration was analyzed by an enzymatic, photometric assay (Konelab CHOLESTEROL kit, Thermo Electron Co, Finland).
Glucose was measured by colorimetric enzyme assay (GOD-PAP, Roche Diagnostics. Plasma triglycerides were measured by GPO-PAP (glycerol phosphate oxidase coupled to phenol and 4-aminophenazone) method.
Total cholesterol was measured using an enzymatic assay (CHOD-PAP method, Boehringer Mannheim, Germany).
Triglycerides (TG) were determined using a Trinder-based (GPO-PAP) colorimetric end point assay (TR 3823, Randox Laboratories Ltd ,UK).
Total cholesterol (TC) was determined using a Trider-based (CHOD-PAP) colorimetric end-point assay (CH 3810, Randox Laboratories Ltd ,UK).
